Praluent Coverage: Being First May Not Matter As Payers Await Repatha
Executive Summary
The pricing advantage that might have been available to Praluent as first-in-class is undercut by the fact that it only has about a month’s lead time over the competition.
You may also be interested in...
Priority Review Voucher Expansion Could Be Bad, Program Creator Says
Congress should be cautious about adding categories because more vouchers will mean a lower price for companies who want to sell them, Duke economist Ridley and Novartis exec Régnier argue.
Preferred Rivals: Express Scripts Covers Both Repatha And Praluent
Pharmacy benefit manager will cover both Amgen’s Repatha (evolocumab) and Regeneron/Sanofi’s Praluent(alirocumab) instead of picking a preferred PCSK9 inhibitor, as it did for hepatitis C.
Sanofi's Praluent And Amgen's Repatha Now Set For Battle In Europe, US
Praluent and Repatha are ready for a transatlantic showdown after regulatory approvals in Europe and US, but the jury remains out on which PCSK9 inhibitor will gain the upper hand.